- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Orchestra BioMed wins FDA breakthrough nod for pacemaker in hypertension | - | MassDevice | ||
| 23.04. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 | 1 | GlobeNewswire (USA) | ||
| 26.03. | Jefferies senkt Kursziel für Orchestra BioMed wegen Finanzierungskosten | 1 | Investing.com Deutsch | ||
| 26.03. | Jefferies cuts Orchestra BioMed stock price target on financing costs | 1 | Investing.com | ||
| 12.03. | Chardan reiterates Orchestra BioMed stock rating on trial focus | 2 | Investing.com | ||
| 12.03. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update | 744 | GlobeNewswire (Europe) | $106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics'... ► Artikel lesen | |
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 12.03. | Orchestra BioMed Holdings, Inc. - 10-K, Annual Report | 5 | SEC Filings | ||
| 03.03. | Orchestra BioMed to present hypertension therapy data at medical meetings | 3 | Investing.com | ||
| 03.03. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT | 1 | GlobeNewswire (USA) | ||
| 13.02. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 06.02. | Orchestra BioMed Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.01. | Orchestra BioMed to pick up $21M through Haemonetics' acquisition of Vivasure | 2 | MassDevice | ||
| 12.01. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.01. | Assessing Orchestra BioMed Holdings: Insights From 4 Financial Analysts | 1 | Benzinga.com | ||
| 10.12.25 | TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio | 1 | Investing.com | ||
| 08.12.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting | 220 | GlobeNewswire (Europe) | Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension... ► Artikel lesen | |
| 26.11.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.11.25 | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11.25 | Orchestra BioMed Holdings Q3 Loss Widens | 1 | RTTNews |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 29,035 | +1,84 % | Qiagen senkt Jahresprognose: QuantiFERON belastet, Aktie im Minus | Qiagen hat im ersten Quartal 2026 vorläufigen Zahlen zufolge einen Umsatz von 492 Millionen Dollar erzielt, ein Plus von 2 Prozent auf berichteter Basis, bei konstanten Wechselkursen jedoch ein Minus... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,960 | 0,00 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| AVALYN PHARMA | 29,015 | 0,00 % | Avalyn Pharma Prices Upsized $300 Mln IPO At $18 Per Share | WASHINGTON (dpa-AFX) - Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 16.67 million shares at a price... ► Artikel lesen | |
| ALUMIS | 24,690 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| ERASCA | 10,640 | 0,00 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,240 | 0,00 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| TANGO THERAPEUTICS | 21,530 | 0,00 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| EVOTEC | 5,240 | +4,70 % | EQS-News: Evotec SE: Evotec kündigt Wechsel im Finanzvorstand an | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec kündigt Wechsel im Finanzvorstand an
24.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
| IMMUNOVANT | 27,150 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,470 | 0,00 % | Summit Therapeutics Inc. - 10-Q, Quarterly Report | ||
| TARSUS PHARMACEUTICALS | 63,66 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | ||
| PRAXIS PRECISION MEDICINES | 318,57 | 0,00 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| RECURSION PHARMACEUTICALS | 3,465 | 0,00 % | Recursion Pharmaceuticals: Recursion Announces Board Transition | Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson... ► Artikel lesen | |
| CG ONCOLOGY | 66,75 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen |
Das Unternehmen ORCHESTRA BIOMED HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.